Therapeutic Family Presence Key in Tx of Acute Deterioration in ER

Share this content:
Therapeutic Family Presence Key in Tx of Acute Deterioration in ER
Therapeutic Family Presence Key in Tx of Acute Deterioration in ER

TUESDAY, Jan. 31, 2017 (HealthDay News) -- For deteriorating adult patients in the emergency department, no family presence and physical family presence result in predominantly negative clinician-family-patient interactions, while therapeutic family presence results in positive clinician-family-patient interactions, according to a study published online Jan. 19 in the Journal of Clinical Nursing.

Megan J. Youngson, R.N., from Deakin University in Burwood, Australia, and colleagues examined the characteristics and interactions of clinicians, patients, and family members during management of deteriorating adult patients in the emergency department. The authors observed five clinical deterioration episodes within a 50-bed emergency department.

The researchers found that while family are present during a patient's episode of deterioration, presence, roles, and engagement describe the interactions between clinicians, family members, and patients. Presence was categorized as no presence, physical presence, or therapeutic presence. During a patient's deterioration episode, clinicians and family members moved through primary, secondary, and tertiary roles. Engagement was either superficial or deep. A complex interplay was identified between presence, roles, and engagement, with each affecting the form of the other variables.

"This study identified three types of presence that occurred during a patient's episode of deterioration," the authors write. "No presence and physical presence resulted in predominantly negative clinician-family-patient interactions, while therapeutic presence resulted in positive clinician-family-patient interactions."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »